-
公开(公告)号：US11214605B2
公开(公告)日：2022-01-04
申请号：US16832183
申请日：2020-03-27
Applicant: APOGENIX AG
Inventor： Oliver Hill , Christian Gieffers , Meinolf Thiemann
IPC: C12N15/62 , C12N15/79 , C07K14/705 , C07K14/525 , C07K16/00 , A61K38/00
Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
公开(公告)号：US20200247860A1
公开(公告)日：2020-08-06
申请号：US16832183
申请日：2020-03-27
Applicant: Apogenix Ag
Inventor： Oliver Hill , Christian Gieffers , Meinolf Thiemann
IPC: C07K14/525 , C07K14/705 , C07K16/00 , C12N15/79 , C12N15/62
Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
公开(公告)号：US10683338B2
公开(公告)日：2020-06-16
申请号：US15958180
申请日：2018-04-20
Applicant: Apogenix AG
Inventor： Christian Gieffers , Oliver Hill , Meinolf Thiemann , Tim Schnyder
Abstract: Provided herein are specific TL1A receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TL1A-associated disease or disorder. The TL1A receptor agonist proteins provided herein comprise three soluble TL1A domains and an Fc fragment. The TL1A receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
公开(公告)号：US10266600B2
公开(公告)日：2019-04-23
申请号：US15335297
申请日：2016-10-26
Applicant: APOGENIX AG
Inventor： Harald Fricke , Christian Gieffers , Jaromir Sykora
IPC: G01N33/574 , C07K16/28 , A61K39/00
Abstract: The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease.
-
公开(公告)号：US20180244752A1
公开(公告)日：2018-08-30
申请号：US15957279
申请日：2018-04-19
Applicant: Apogenix AG
Inventor： Christian GIEFFERS , Oliver HILL , Meinolf THIEMANN , Tim SCHNYDER
IPC: C07K14/705
Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
Patent Agency Ranking
公开(公告)号：US20180237495A1
公开(公告)日：2018-08-23
申请号：US15955086
申请日：2018-04-17
Applicant: Apogenix AG
Inventor： Christian GIEFFERS , Oliver HILL , Meinolf THIEMANN , Tim SCHNYDER
IPC: C07K14/705 , A61K38/19 , C07K19/00 , A61K38/17
CPC classification number: C07K14/70578 , A61K38/1774 , A61K38/191 , C07K14/70575 , C07K19/00 , C07K2319/034 , C07K2319/30 , C07K2319/32 , C07K2319/50 , C07K2319/74
Abstract: Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder. The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fe fragment. The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeuctic, diagnostic and/or research applications.
-
公开(公告)号：US20200331979A1
公开(公告)日：2020-10-22
申请号：US16898122
申请日：2020-06-10
Applicant: Apogenix AG
Inventor： Christian GIEFFERS , Oliver HILL , Meinolf THIEMANN , Tim SCHNYDER
Abstract: Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder. The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment. The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
公开(公告)号：US10793616B2
公开(公告)日：2020-10-06
申请号：US15795020
申请日：2017-10-26
Applicant: Apogenix AG
Inventor： Oliver Hill , Christian Gieffers , Meinolf Thiemann , Tim Schnyder
IPC: C07K14/705 , A61K38/00
Abstract: Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder. The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment. The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
公开(公告)号：US10683332B2
公开(公告)日：2020-06-16
申请号：US15958707
申请日：2018-04-20
Applicant: Apogenix AG
Inventor： Christian Gieffers , Oliver Hill , Meinolf Thiemann , Tim Schnyder
Abstract: Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder. The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment. The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
10.发明授权公开(公告)号：US10533043B2
公开(公告)日：2020-01-14
申请号：US15957279
申请日：2018-04-19
Applicant: Apogenix AG
Inventor： Christian Gieffers , Oliver Hill , Meinolf Thiemann , Tim Schnyder
IPC: C07K14/705 , A61K38/00 , C12N15/00
Abstract: Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder. The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment. The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
-
-
-
-
-
-
-
-
-
Search Results
48
records
(took 0.027 seconds)
